Prothena Corp (PRTA)

• Market cap: $467M
• 1 day: -1.73%
• 5 days: -0.22%
• 1 month: 4.48%
• 3 months: -9.37%
• 6 months: 4.84%
• Year to date: -1.2%
• 1 year: 6.19%
• 5 years: -86.66%
• 10 years: -81.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Employees: 67